Straits Times Index
2,949.04-24.50(-0.82%)Nikkei
28,966.01-1,202.26(-3.99%)Hang Seng
28,980.21-1,093.96(-3.64%)
Geron Corporation (GERN)
| Previous close | 1.8100 |
| Open | 1.8200 |
| Bid | 1.7900 x 45900 |
| Ask | 1.8000 x 21500 |
| Day's range | 1.7300 - 1.8500 |
| 52-week range | 0.7500 - 2.4000 |
| Volume | 3,099,872 |
| Avg. volume | 3,571,913 |
| Market cap | 555.745M |
| Beta (5Y monthly) | 1.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3350 |
| Earnings date | 05 Nov 2020 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.00 |
- Business Wire
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 431,600 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.
- Business Wire
Geron to Present at the B. Riley Securities Virtual Oncology Investor Conference
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the B. Riley Securities Virtual Oncology Investor Conference on Wednesday, January 20, at 3:00 p.m. ET.
- Business Wire
Geron Announces Opening of IMpactMF Phase 3 Clinical Trial in Refractory Myelofibrosis
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the opening for patient screening and enrollment of the IMpactMF Phase 3 clinical trial of imetelstat, a first-in-class telomerase inhibitor, in refractory myelofibrosis (MF).
